Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Long-Term Debt Repayments (2018 - 2023)

Ligand Pharmaceuticals' Long-Term Debt Repayments history spans 10 years, with the latest figure at $76.9 million for Q2 2023.

  • For Q2 2023, Long-Term Debt Repayments rose 28.2% year-over-year to $76.9 million; the TTM value through Sep 2024 reached $76.9 million, changed 0.0%, while the annual FY2023 figure was $76.9 million, 70.55% down from the prior year.
  • Long-Term Debt Repayments for Q2 2023 was $76.9 million at Ligand Pharmaceuticals, up from $37.6 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $203.2 million in Q1 2020 and bottomed at $2.4 million in Q3 2021.
  • The 5-year median for Long-Term Debt Repayments is $52.3 million (2021), against an average of $74.3 million.
  • The largest annual shift saw Long-Term Debt Repayments crashed 46.45% in 2021 before it skyrocketed 1482.43% in 2022.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $27.3 million in 2019, then crashed by 30.47% to $19.0 million in 2020, then crashed by 87.48% to $2.4 million in 2021, then surged by 1482.43% to $37.6 million in 2022, then skyrocketed by 104.15% to $76.9 million in 2023.
  • Per Business Quant, the three most recent readings for LGND's Long-Term Debt Repayments are $76.9 million (Q2 2023), $37.6 million (Q3 2022), and $59.9 million (Q2 2022).